First Cancer Trial Launched Using Car T Cells Engineered with a Safety Switch

Bellicum Pharmaceuticals, Inc. announced today that the first clinical study is underway of a Chimeric Antigen Receptor T Cell therapy that incorporates a safety switch to enable rapid elimination of the administered T cells if they threaten the life or health of the patient.

http://ift.tt/1ivvdEL